Induction of specific T cell tolerance by Fas ligand-expressing antigen- presenting cells

Journal of Immunology

Volumn 162, Issue 3, 1999, Pages 1423-1430

  Zhang, Huang Ge ^a   Su, Xiao ^a   Liu, Di ^a   Liu, Weimin ^a   Yang, Pingar ^a   Wang, Zheng ^a   Edwards, Carl K ^b   Bluethmann, Horst ^c   Mountz, John D ^d   Zhou, Tong ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b AMGEN INC   (United States)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

^d BIRMINGHAM VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN; FAS LIGAND;

ANIMAL CELL; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; APOPTOSIS; ARTICLE; AUTOIMMUNE DISEASE; CELL FUNCTION; FEMALE; GRAFT REJECTION; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; TRANSGENIC MOUSE;

ANIMALS; ANTIGEN-PRESENTING CELLS; ANTIGENS, CD95; APOPTOSIS; FAS LIGAND PROTEIN; FEMALE; H-2 ANTIGENS; H-Y ANTIGEN; IMMUNE TOLERANCE; ISOANTIGENS; LYMPHOID TISSUE; MACROPHAGES; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; MICE, INBRED MRL LPR; MICE, TRANSGENIC; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES;

EID: 0033082545     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (61)

1. Bretscher, P., and M. Cohn. 1970. A theory of self-nonself discrimination. Science 169:1042.
2. Lafferty, K. J., and R. G. Gill. 1993. The maintenance of self-tolerance. Immunol. Cell. Biol. 71:209.
3. Jenkins, M. K., and R. H. Schwartz. 1987. Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo. J. Exp. Med. 165:302.
4. Liu, Y., and P. S. Linsley. 1992. Costimulation of T-cell growth. Curr. Opin. Immunol. 4:265.
5. June, C. H., J. A. Ledbetter, P. S. Linsley, and C. B. Thompson. 1990. Role of the CD28 receptor in T-cell activation. Immunol. Today 11:211.
6. June, C. H., J. A. Bluestone, L. M. Nadler, and C. B. Thompson. 1994. The B7 and CD28 receptor families. Immunol. Today 15:321.
7. Linsley, P. S., and J. A. Ledbetter. 1993. The role of the CD28 receptor during T cell responses to antigen. Annu. Rev. Immunol. 11:191.
8. Savegh, M. H., E. Akalin, W. W. Hancock, M. E. Russell, C. B. Carpenter, P. S. Linsley, and L. A. Turka. 1995. CD28-B7 blockade after alloantigenic challenge in vivo inhibits Th1 cytokines but spares Th2. J. Exp. Med. 181:1869.
9. Corry, D. B., S. L. Reiner, P. S. Linsley, and R. M. Locksley. 1994. Differential effects of blockade of CD28-B7 on the development of Th1 or Th2 effector cells in experimental leishmaniasis. J. Immunol. 153:4142.
10. Lu, P., X. Zhou, S, J. Chen, M. Moorman, S. C. Morris, F. D. Finkelman, P. S. Linsley, J. F. Urban, and W. C. Gause. 1994. CTLA-4 ligands are required to induce an in vivo interleukin 4 response to a gastrointestinal nematode parasite. J. Exp. Med. 180:693.
11. Guerder, S., D. E. Picarella, P. S. Linsley, and R. A. Flaverll. 1994. Costimulator B7-1 confers antigen-presenting-cell function to parenchymal tissue and in conjunction with tumor necrosis factor α leads to autoimmunity in transgenic mice. Proc. Natl. Acad. Sci. USA 91:5138.
12. Guerder, S., J. Meyerhoff, and R. Flavell. 1994. The role of the T cell costimulator B7-1 in autoimmunity and the induction and maintenance of tolerance to peripheral antigen. Immunity 1:155.
13. Harlan, D. M., H. Hengartner, M. L. Huang, Y. H. Kang, R. Abe, R. W. Moreadith, H. Pircher, G. S. Gray, P. S. Ohashi, and G. J. Freeman. 1994. Mice expressing both B-7 and viral glycoprotein on pancreatic β cells along with glycoprotein-specific transgenic T cells develop diabetes due to a breakdown of T-lymphocyte unresponsiveness. Proc. Natl. Acad. Sci. USA 91:3137.
14. Finkelman, F. D., A. Lees, R. Birnbaum, W. C. Gause, and S. C. Morris. 1996. Dendritic cells can present antigen in vivo in a tolerogenic or immunogenic fashion. J. Immunol. 157:1406.
15. Lafferty, K. J., S. J. Prowse, C. J. Simeonovic, and H. S. Warren. 1983. Immunobiology of tissue transplantation: a return to the passenger leukocyte concept. Annu. Rev. Immunol. 1:143.
16. Talmage, D. W., G. Dart, J. Radovich, and K. J. Lafferty. 1976. Activation of transplant immunity; effect of donor leukocytes on thyroid allograft rejection. Science 191:385.
17. Lafferty, K. J., A. Bootes, G. Dart, and D. W. Talmage. 1976. Effect of organ culture on the survival of thyroid allografts in mice. Transplantation 22:138.
18. La Rosa, F. G., and D. W. Talmage. 1983. The failure of a major histocompatibility antigen to stimulate thyroid allograft reaction after culture in oxygen. J. Exp. Med. 157:898.
19. Warrens, A. N., G. Lombardi, and R. I. Lechler. 1994. Presentation and recognition of major and minor histocompatibility antigens. Transplant. Immunol. 2:103.
20. Lenschow, D. J., Y. Zeng, J. R. Thistlethwaite, A. Montag, W. Brady, M. G. Gibson, P. S. Linsley, and J. A. Bluestone. 1992. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4Ig. Science 257:789.
21. Turka, L. A., P. S. Linsley, H. Lin, W. Brady, J. M. Leiden, R. Q. Wei, M. L. Gibson, X. G. Zheng, S. Myrdal, and D. Gordon. 1992. T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo. Proc. Natl. Acad. Sci. USA 89:11102.
22. Watanabe-Fukunaga, R., C. I. Brannan, N. G. Copeland, N. A. Jenkins, and S. Nagata. 1992. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 356:314.
23. Takahashi, T., M. Tanaka, C. I. Brannan, N. A. Jenkins, N. G. Copeland, T. Suda, and S. Nagata. 1994. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell 76:969.
24. Singer, G. G., and A. K. Abbas. 1994. The Fas antigen is involved in peripheral but not thymic deletion of T lymphocytes in T cell receptor transgenic mice. Immunity 1:365.
25. Zhou, T., H. Bluethmann, J. Eldridge, M. Brockhaus, K. Berry, and J. D. Mountz. 1991. Abnormal thymocyte development and production of autoreactive T cells in T cell receptor transgenic autoimmune mice. J. Immunol. 147:466.
26. Zhou, T., H. Bluethmann, J. Zhang, C. K. Edwards, and J. D. Mountz. 1992. Defective maintenance of T cell tolerance to a superantigen in MRL-lpr/lpr mice. J. Exp. Med. 176:1063.
27. Zhou, T., C. Weaver, P. S. Linsley, and J. D. Mountz. 1994. T cells of staphy-lococcal enterotoxin B-tolerized autoimmune MRL-lpr/lpr mice require co-stimulation through the B7-CD28/CTLA-4 pathway for activation and can be reanergized in vivo by stimulation of the T cell receptor in the absence of this costimulatory signal. Eur. J. Immunol. 24:1019.
28. Wu, J., T. Zhoti, J. Zhang, J. He, W. C. Gause, and J. D. Mountz. 1994. Correction of accelerated autoimmune disease by early replacement of the mutated lpr gene with the normal Fas apoptosis gene in the T cells of transgenic MRL-lpr/lpr mice. Proc. Natl. Acad. USA 91:2344.
29. Zhou, T., C. K. Edwards, and J. D. Mountz. 1995. Prevention of age-related T cell apoptosis defect in CD2 fas-transgenic mice. J. Exp. Med. 182:129.
30. Itoh, N., S. Yonehara, A. Ishii, M. Yonehara, S. Mizushima, M. Smeshima, A. Hase, Y. Seto, and S. Nagata. 1991. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 66:2233.
31. Suda, T., T. Takahashi, P. Golstein, and S. Nagata. 1993. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 75:1169.
32. Ogasawara, J., R. Watanabe-Fukunaga, M. Adachi, A. Matsuzawa, T. Kasugai, Y. Kitamura, N. Itoh, T. Suda, and S. Nagata. 1993. Lethal effect of the anti-Fas antibody in mice. Nature 364:806.
33. Ju, S. T., D. J. Panka, H. Cui, R. Erringer, M. El-Khatib, D. H. Sherr, B. Z. Stanger, and A. Marshak-Rothstein. 1995. Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature 373:444.
34. Brunner, T., R. J. Mogil, D. LaFace, N. J. Yoo, A. Mahboubi, F. Echeverri, S. J. Martin, W. R. Force, D. H. Lynch, and C. F. Ware. 1995. Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature 373:385.
35. Dhein, J., H. Walczak, C. Baumler, K. M. Debatin, and P. H. Krammer 1995. Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). Nature 373:438.
36. + lymphocytes delete activated macrophages through the Fas/APO-1 antigen pathway. Proc. Natl. Acad. Sci. USA 92:11225.
37. + T cells apoptosis: a possible mechanism of bystander cell death in HIV infection. J. Immunol. 158:2456.
38. Badley, A. D., J. A. McElhinny, P. J. Leibson, D. H. Lynch, M. R. Alderson, and C. V. Paya. 1996. Upregulation of Fas ligand expression by human immunodeficiency virus in human macrophages mediates apoptosis of uninfected T lymphocytes. J. Virol. 70:199.
39. Schular, G., B. Thurner, and N. Romani. 1997. Dendritic cells: from ignored cells to major players in T-cell-mediated immunity. Int. Arch. Allergy Immunol. 112: 317.
40. Lu, L., S. Oian, P. A. Hershberger, W. A. Rudert, D. H. Lynch, and A. W. Thomson. 1997. Fas Ligand (CD95L) and B7 expression on dendritic cells provide counter-regulatory signals for T cell survival and proliferation. J. Immunol. 158:5676.
41. Griffith, T. S., T. Brunner, S. M. Fletcher, D. R. Green, and T. A. Ferguson. 1995. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 270: 1158.
42. Bellgrau, D., D. Gold, H. Selawry, J. Moore, A. Franzusoff, and R. C. Duke. 1995. A role of CD95 ligand in preventing graft rejection. Nature 377:630.
43. Griffith, T. S., J. Yu, J. M. Herndon, D. R. Green, and T. A. Ferguson. 1996. CD95-induced apoptosis of lymphocytes in an immune privileged site induces immunological tolerance. Immunity 5:7.
44. Head, J. R., W. B. Neaves, and R. E. Billingham. 1983. Immune privilege in the testis. I. Basic parameters of allograft survival. Transplantation 36:423.
45. Maddocks, S., and B. P. Setchell. 1990. Recent evidence for immune privilege in the testis. J. Reprod. Immunol 18:9.
46. Benson, J. L., and J. Y. Niederkom. 1992. Immune privilege in the anterior chamber of the eye: alloantigens and tumour-specific antigens presented into the anterior chamber simultaneously induced suppression and activation of delayed hypersensitivity to the respective antigens. Immunology 77:189.
47. Streilein, J. W. 1993. Immune privilege as the result of local tissue barriers and immunosuppressive microenvironments. Curr. Opin. Immunol. 5:428.
48. Lau, H. T., M. Yu, A. Fontana, and C. J. Stoeckert. 1996. Prevention of islet allograft rejection with engineered myoblasts expressing Fas ligand in mice. Science 273:109.
49. Kang, S. M., D. B. Schneider, Z. Lin, D. Hanahan, D. A. Dichek, P. G. Stock, and S. Baekkeskov. 1997. Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nat. Med. 3:738.
50. Biancone, L., A. D. Martino, V. Orlandi, P. G. Conaldi, A. Toniolo, and G. Camussi. 1997. Development of inflammatory angiogenesis by local stimulation of Fas in vivo. J. Exp. Med. 186:147.
51. Allison, J., H. M. Georgiou, A. Strasser, and D. L. Vaux. 1997. Transgenic expression of CD95 ligand on islet β cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts. Proc. Natl. Acad. Sci. USA 94:1943.
52. Edwards, C. K., T. Zhou, J. Zhang, T. J. Baker, M. De, R. E. Long, D. R. Borcherding, T. L. Bowlin, H. Bleuthmann, and J. D. Mountz. 1996. Inhibition of superantigen-induced proinflammatory cytokine production and inflammatory arthritis in MRL-lpr/lpr mice by a transcriptional inhibitor of TNF-α. J. Immunol. 157:1758.
53. Zhang, H. G., G. Bilbao, T. Zhou, J. L. Contreras, J. Gomez-Navarro, M. Feng, I. Saito, J. D. Mountz, and D. T. Curiel. 1998. Application of a Fas ligand encoding a recombinant adenovirus vector for prolongation of transgene expression. J. Virol. 72:2483.
54. Teh, H. S., P. Kisielow, B. Scott, H. Kishi, Y. Uematsu, H. Bluthmann, and H. von Boehmer. 1988. Thymic major histocompatibility complex antigens and the αβ T-cell receptor determine the CD4/CD8 phenotype of T cells. Nature 335:229.
55. Zhang, H. G., D. Liu, Y. Heike, Z. Wang, P. A. Yang, D. T. Curiel, T. Zhou, and J. D. Mountz. 1998. Induction of adenovirus-specific T cell tolerance by Fas ligand expression macrophages. Nat. Biotechnol. 16:1045.
56. Tanaka, M., T. Suda, T. Yatomi, N. Nakamura, and S. Nagata. 1997. Lethal effect of recombinant human Fas ligand in mice pretreated with Propionibacterium acnes. J. Immunol. 158:2303.
57. Sato, K., F. Kimura, Y. Nakamura, H. Murakami, M. Yoshida, M. Tanaka, S. Nagata, Y. Kanatani, N. Wakimoto, N. Nagata et al. 1996. An aggressive nasal lymphoma accompanied by high levels of soluble Fas ligand. Br. J. Haematol. 94:379.
58. Strand, S., W. J. Hofmann, H. Hug, M. Muller, G. Otto, D. Strand, S. M. Mariani, W. Stremmel, P. H. Krammer, and P. R. Galle. 1997. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells: a mechanism of immune evasion? Nat. Med. 2:1361.
59. Arai, H., S. Y. Chan, D. K. Bishop, and G.J. Nabel. 1997. Inhibition of the alloantibody response by CD95 ligand. Nat. Med. 3:843.
60. Suda, T., M. Tanaka, K. Miwa, and S. Nagata. 1996. Apoptosis of mouse naive T cells induced by recombinant soluble Fas ligand and activation-induced resistance to Fas ligand. J. Immunol 157:3918.
61. Suss, G., and K. Shortman. 1996. A subclass of dendritic cells kills CD4 T cells via Fas/Fas ligand-induced apoptosis. J. Exp. Med. 183:1789.